---
title: "Claris Lifesciences Ltd (533288) — Share Price, Financials & Analysis"
symbol: "533288"
company: "Claris Lifesciences Ltd"
canonical: "https://tapetide.com/stocks/533288"
isin: "INE562G01018"
bse_code: "533288"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T19:02:38.584Z"
---

# Claris Lifesciences Ltd (533288)

Canonical page: https://tapetide.com/stocks/533288

## Company

- **BSE Code:** 533288
- **ISIN:** INE562G01018
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2010-12-20
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** clarislifesciences.com

## About

Claris Lifesciences Limited is engaged in manufacturing of drugs and pharmaceutical products.

## Latest Price

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.

## Growth Rates

| Metric | 1Y | 5Y |
| --- | --- | --- |
| net income growth | 95% | 14% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 158 | 187 | 197 | 26 | 18 | 1 | 2 | 5 | 3 | 3 | 4 | 2 |
| Expenses | 134 | 141 | 184 | 65 | 39 | 16 | 27 | 39 | 21 | 22 | 16 | 375 |
| Operating Profit | 24 | 46 | 13 | -40 | -21 | -15 | -25 | -34 | -19 | -19 | -11 | -373 |
| OPM % | 15 | 25 | 6 | -155 | -114 | -1104 | -1411 | -752 | -676 | -611 | -264 | -18034 |
| Other Income | 14 | 8 | 21 | 33 | 17 | 40 | 56 | 44 | 53 | 38 | 1865 | 59 |
| Interest | 10 | 10 | 11 | 1 | 2 | 1 | 4 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 10 | 4 | 1 | 1 | 2 | 0 | 1 | 2 | 1 | 1 | 1 |
| Profit before tax | 18 | 34 | 18 | -8 | -7 | 22 | 27 | 8 | 32 | 17 | 1852 | -316 |
| Tax % | 30 | 37 | 24 | -276 | -91 | 1 | -20 | -121 | -17 | -16 | 1 | 1 |
| Net Profit | 10 | 19 | 12 | -70 | -1 | 22 | 32 | 19 | 37 | 19 | 1840 | -317 |
| EPS in Rs | 1.91 | 3.53 | 2.2 | -12.84 | -0.11 | 4.03 | 5.94 | 3.4 | 6.77 | 3.52 | 337.24 | -58.17 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 740.49 | 767.36 | 667.76 | 799.76 | 133.16 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 494.25 | 502.55 | 521.49 | 661.69 | 267.16 | 10.64 | 25.19 | 12.47 | 1.46 | 0.31 |
| Operating Profit | 246.24 | 264.81 | 146.27 | 138.07 | -134 | -10.64 | -25.19 | -12.47 | -1.46 | -0.31 |
| OPM % | 33.25 | 34.51 | 21.9 | 17.26 | -100.63 | — | — | — | — | — |
| Other Income | 15.33 | 10.29 | 78.76 | 103.71 | 80.99 | 120.14 | 42.57 | 7.63 | 0.46 | 0.04 |
| Interest | 55.43 | 65.05 | 52.19 | 48.26 | 5.48 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 54.68 | 74.27 | 65.35 | 49.05 | 3.86 | 0.14 | 0.1 | 0 | 0 | 0 |
| Profit before tax | 151.46 | 135.78 | 107.49 | 144.47 | -62.35 | 109.36 | 17.28 | -4.84 | -1 | -0.27 |
| Tax % | 16.64 | 23.47 | 20.54 | -8.45 | -36.74 | -0.51 | 9.9 | 54.75 | 401 | 0 |
| Net Profit | 126.25 | 103.91 | 84.41 | 149.48 | -39.44 | 109.93 | 15.56 | -7.49 | -5.01 | -0.27 |
| EPS in Rs | 19.78 | 16.28 | 13.23 | 27.39 | -7.23 | 20.15 | 3.12 | -1.37 | -0.92 | -0.05 |
| Dividend Payout % | 10.11 | 12.28 | 68.05 | 0 | -27.67 | 9.93 | 64.2 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 63.82 | 63.82 | 63.82 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 |
| Reserves | 988.29 | 1085.05 | 1340.48 | 1262.14 | 864.94 | 965.37 | -53.86 | -60.94 | -65.96 | -66.23 |
| Borrowings | 408.64 | 542.09 | 267.78 | 533.82 | 598.73 | 21.56 | 0 | 0 | 20.97 | 21.01 |
| Other Liabilities | 269.86 | 311.34 | 438.84 | 333.25 | 229.06 | 740.65 | 23.31 | 28.1 | 0.4 | 0.43 |
| Total Liabilities | 1730.61 | 2002.3 | 2110.92 | 2183.78 | 1747.3 | 1782.15 | 24.02 | 21.73 | 9.98 | 9.78 |
| Fixed Assets | 663.27 | 870.6 | 571.57 | 1074.29 | 866.17 | 56.41 | 0 | 0 | 0 | 0 |
| CWIP | 41.92 | 174.27 | 173.29 | 2.83 | 10.42 | 2.4 | 0 | 0 | 0 | 0 |
| Investments | 0.02 | 0.02 | 818.32 | 533.92 | 308.28 | 291.26 | 0 | 0 | 0 | 0 |
| Other Assets | 1025.4 | 957.41 | 547.74 | 572.74 | 562.43 | 1432.08 | 24.02 | 21.73 | 9.98 | 9.78 |
| Total Assets | 1730.61 | 2002.3 | 2110.92 | 2183.78 | 1747.3 | 1782.15 | 24.02 | 21.73 | 9.98 | 9.78 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -18.93 | 334.18 | 143.38 | -41.43 | 20.46 | 179.35 | -5.82 | -0.15 | 6.17 | -0.11 |
| Cash from Investing Activity | -221.22 | -436.61 | 197.01 | -122.86 | 56.8 | -58.46 | -133.48 | 0.35 | 0.41 | 0.05 |
| Cash from Financing Activity | -24.2 | 58.27 | -342.88 | 152.21 | 22.28 | -105.49 | -13.14 | 0 | -6.67 | -0.01 |
| Net Cash Flow | -264.35 | -44.16 | -2.49 | -12.07 | 99.54 | 15.41 | -152.44 | 0.21 | -0.09 | -0.06 |
| Free Cash Flow | -253.43 | -108.85 | 924.15 | -258.7 | -90.95 | 108.8 | 3.18 | -0.15 | 6.17 | -0.11 |
| CFO/OP | -1 | 136 | 110 | 6 | -40 | -2440 | 12 | 1 | -41 | 35 |

### Ratios

| Item | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 135.04 | 108.56 | 85.55 | 104.58 | 458.91 | — | — | — | — | — |
| Inventory Days | 227.47 | 268.54 | 66.44 | 96.51 | 337.48 | — | — | — | — | — |
| Days Payable | 107.34 | 156.09 | 110.97 | 130.52 | 518.84 | — | — | — | — | — |
| Cash Conversion Cycle | 255.17 | 221.01 | 41.02 | 70.57 | 277.55 | — | — | — | — | — |
| Working Capital Days | 199.37 | 152.54 | -62.96 | 71.29 | 336.3 | — | — | — | — | — |
| ROCE % | 15.17 | 12.74 | 8.29 | 9.95 | -1.23 | 8.54 | 1.92 | — | -62.31 | -2.85 |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Dec 2017 |
| --- | --- | --- |
| Promoters | 50.13% | 50.13% |
| FIIs | 26.48% | 26.02% |
| DIIs | 1.86% | 1.94% |
| Public | 21.53% | 21.91% |
| No. of Shareholders | 19659 | 17032 |

### Quarterly

| Category | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 60.99% | 52.56% | 50.13% | 50.13% | 50.13% | 50.13% | 50.13% |
| FIIs | 20.29% | 25.43% | 25.86% | 26.48% | 26.22% | 25.62% | 26.02% |
| DIIs | 1.35% | 1.35% | 1.49% | 1.86% | 1.86% | 1.94% | 1.94% |
| Public | 17.36% | 20.66% | 22.52% | 21.53% | 21.79% | 22.31% | 21.91% |
| No. of Shareholders | 20983 | 20549 | 20117 | 19659 | 18198 | 17902 | 17032 |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 20 Mar 2018 - Exit Letter of Offer to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited ('Company') for the acquisition of 22,88,697 (Twenty Two Lakh … | [Exit Letter Of Offer 20 Mar 2018 - Exit Letter of Offer to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited ('Company') for the acquisition of 22,88,697 (Twenty Two Lakh …](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3998dcb2-77a1-4b62-8808-5bb5bed61216.pdf) |
| 20 Mar 2018 - Exit Letter of Offer to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited ('Company') for the acquisition of 22,88,697 (Twenty Two Lakh … | [Exit Letter Of Offer 20 Mar 2018 - Exit Letter of Offer to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited ('Company') for the acquisition of 22,88,697 (Twenty Two Lakh …](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/3/3998dcb2-77a1-4b62-8808-5bb5bed61216.pdf) |
| 16 Oct 2025 - Amalgamation effective Oct 16, 2025; Appointed Date Apr 1, 2024; Record Date Oct 31; 187:100 share swap. | [31St October 2025 As The 'Record Date For The Purpose Of Composite Scheme Of Arrangement 16 Oct 2025 - Amalgamation effective Oct 16, 2025; Appointed Date Apr 1, 2024; Record Date Oct 31; 187:100 share swap.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e4a2d64b-13f7-4753-a7c8-5056cf2d1490.pdf) |
| 16 Oct 2025 - Amalgamation effective 16 Oct 2025; appointed date 01 Apr 2024; record date 31 Oct 2025; 187:100 swap. | [Board Meeting Outcome for Composite Scheme Of Arrangement By And Amongst Mangalore Chemicals & Fertilizers Limited, Paradeep Phosphates Limited And Their Respective Shareholders And Creditors 16 Oct 2025 - Amalgamation effective 16 Oct 2025; appointed date 01 Apr 2024; record date 31 Oct 2025; 187:100 swap.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6c65e98-c603-4ccf-95fc-4403b98e4d3c.pdf) |
| 14 Oct 2025 - Zuari sold 2,90,37,000 MCFL shares on 13 Oct 2025; stake falls from 54.03% to 29.53%. | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 14 Oct 2025 - Zuari sold 2,90,37,000 MCFL shares on 13 Oct 2025; stake falls from 54.03% to 29.53%.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/63CFC072_4BD3_4ECD_AD51_73132A7C2C16_100253.pdf) |
| 13 Oct 2025 - NCLT-sanctioned composite scheme effective Oct 13, 2025; MCF to amalgamate into Paradeep; Effective Date2 Oct 16, 2025. | [Announcement under Regulation 30 (LODR)-Scheme of Arrangement 13 Oct 2025 - NCLT-sanctioned composite scheme effective Oct 13, 2025; MCF to amalgamate into Paradeep; Effective Date2 Oct 16, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/29720e7b-7174-43e5-bfe7-54f83b417089.pdf) |
| 12 Mar 2018 - Exit Offer Public Announcement to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited (the 'Company') made by Athanas Enterprise Private Limited ('AEPL' … | [Announcement under Regulation 30 (LODR)-Updates 12 Mar 2018 - Exit Offer Public Announcement to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited (the 'Company') made by Athanas Enterprise Private Limited ('AEPL' …](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49a9af0b-f03b-4072-80ba-e902a056333e.pdf) |
| 12 Mar 2018 - Exit Offer Public Announcement to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited (the 'Company') made by Athanas Enterprise Private Limited ('AEPL' … | [Announcement under Regulation 30 (LODR)-Updates 12 Mar 2018 - Exit Offer Public Announcement to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited (the 'Company') made by Athanas Enterprise Private Limited ('AEPL' …](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/3/49a9af0b-f03b-4072-80ba-e902a056333e.pdf) |
| 12 Mar 2018 - Delisting Announcement with respect to voluntary delisting of the equity shares of Claris Lifesciences Limited (the 'Company') from BSE Limited in accordance with the provisions … | [Announcement under Regulation 30 (LODR)-Updates 12 Mar 2018 - Delisting Announcement with respect to voluntary delisting of the equity shares of Claris Lifesciences Limited (the 'Company') from BSE Limited in accordance with the provisions …](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f916c3f1-a387-4178-934f-cf1b9ed91fec.pdf) |
| 12 Mar 2018 - Delisting Announcement with respect to voluntary delisting of the equity shares of Claris Lifesciences Limited (the 'Company') from BSE Limited in accordance with the provisions … | [Announcement under Regulation 30 (LODR)-Updates 12 Mar 2018 - Delisting Announcement with respect to voluntary delisting of the equity shares of Claris Lifesciences Limited (the 'Company') from BSE Limited in accordance with the provisions …](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/3/f916c3f1-a387-4178-934f-cf1b9ed91fec.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8236a5cd-dc1e-446c-9824-2cdd374c8946.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8e223512-c370-4e5c-af48-e187750f1279.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9507721a-0d35-410b-8d6b-623e2bec2fd1.pdf) |
| Jul 2024 | [Concall - Jul 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8d7989c-0217-4c06-bddb-d8997371fda2.pdf) |
| Feb 2022 | [Concall - Feb 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ce51e2b6-fc89-4155-8f32-4b6246ff53e7.pdf) |
| Aug 2023 | [Concall - Aug 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9a7b55b2-494c-4781-9a38-22716f4d9d55.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2013 from nse](https://archives.nseindia.com/annual_reports/AR_1343_MANGCHEFER_2012_2013_03092013085608.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dcf53125-093f-482e-9767-73cbfaf08a97.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d289dc34-3730-464b-b408-735cdf046131.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dbd14394-a9b4-416c-93d6-53c19ebddff2.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/530011/74429530011.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/530011/69844530011.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/530011/64950530011.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/530011/5300110319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/530011/5300110318.pdf) |
| from bse | [Financial Year 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/530011/5300110317.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:02:38.584Z.